LSE:BARC
LSE:BARCBanks

Is It Time to Reassess Barclays Shares After a 40% Surge in 2025?

If you have been keeping an eye on Barclays, you are probably wondering what to make of its share price rollercoaster lately. Is this the time to buy, hold, or reconsider? The short-term numbers might look underwhelming, with the stock down 3.3% over the past week and off 2.0% in the last month. But step back and the bigger picture tells a very different story. Year to date, Barclays has rocketed nearly 40%, and over the past five years, shares have soared by over 330%. That kind of growth...
LSE:GLEN
LSE:GLENMetals and Mining

Is There Opportunity in Glencore After 14% Share Price Jump?

If you’re standing in front of Glencore stock, wondering whether it’s the moment to buy, hold, or move on, you’re definitely not alone. Glencore has a long history of keeping investors on their toes, swinging from double-digit gains to sharp retracements, and always drawing plenty of headlines along the way. In the past 30 days, Glencore shares have popped 14.0%, which stands out after several months of choppy performance. Despite strong long-term gains over the past five years, including an...
LSE:RIO
LSE:RIOMetals and Mining

A Look at Rio Tinto (LSE:RIO) Valuation Following Recent Share Price Momentum

Rio Tinto Group (LSE:RIO) shares have moved in recent sessions, which has prompted investors to take a closer look at the company’s current valuation and performance. The stock’s returns over the past month and quarter are notable for long-term holders. See our latest analysis for Rio Tinto Group. Rio Tinto Group’s recent run has caught some attention, with the share price climbing more than 8% over the past month and momentum carrying through the quarter. Looking at a broader timeframe, the...
LSE:AZN
LSE:AZNPharmaceuticals

How the Trump-AstraZeneca Drug Price Deal Impacts Its 2025 Share Value

Are you wondering whether now is the right moment to buy, hold, or sell AstraZeneca? You’re not alone. With pharma stocks often in the headlines and government policy always in play, there are plenty of voices offering quick takes. But recent action in AstraZeneca’s share price is hinting at bigger stories beneath the surface, especially for anyone thinking carefully about long-term value. AstraZeneca has been catching attention with a steady climb. Its shares are up 1.0% in the last week and...